Evidence map›Paper›PMID 38802704›Full record

ReviewInfectious diseases and therapy2024

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE.

Sushma Kavikondala, Katrin Haeussler, Xuan Wang, Anne Spellman, Mary T Bausch-Jurken, Pawana Sharma, Mohammadreza Amiri, Anna Krivelyova, Sonam Vats, Maria Nassim and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sushma KavikondalaICON Plc, Burlington, ON, Canada.
Katrin HaeusslerICON Plc, Munich, Germany.
Xuan WangICON Plc, Stockholm, Sweden.
Anne SpellmanData Health Ltd, London, UK.
Mary T Bausch-JurkenModerna, Inc., Cambridge, MA, USA.
Pawana SharmaICON Plc, London, UK.
Mohammadreza AmiriICON Plc, Burlington, ON, Canada.
Anna KrivelyovaICON Plc, London, UK.
Sonam VatsICON Plc, Bangalore, India.
Maria NassimICON Plc, Frankfurt, Germany.
Nitendra KumarICON Plc, Bangalore, India.
Nicolas Van de VeldeModerna, Inc., Cambridge, MA, USA. Nicolas.VandeVelde@modernatx.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImmunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.

methodsA pairwise meta-analysis of 98 studies reporting comparisons of mRNA-1273 (50 or 100 mcg/dose) and BNT162b2 (30 mcg/dose) in IC adults was performed. Outcomes were seroconversion, total and neutralizing antibody titers, and cellular immune responses.

resultsmRNA-1273 was associated with a significantly higher seroconversion likelihood [relative risk, 1.11 (95% CI, 1.08, 1.14); P < 0.0001; I

conclusionHigher-dose mRNA-1273 had increased immunogenicity versus BNT162b2 in IC patients.

Indexed as

BNT162b2Cellular immunityCOVID-19ImmunocompromisedmRNA-1273mRNA vaccineNeutralizing antibodySeroconversionSevere acute respiratory syndrome coronavirus–2Total antibody

Identifiers

PMID38802704
PMCPMC11219657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.